Dr. Christopher T. Chen, MD
Medical Oncology (Medical Oncology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 223
Licensed in California since 2020, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Washington University School of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A169072 (first issued 2020; current) -
Hematology (Internal Medicine) Physician
CA license A169072 (first issued 2020; current) -
Internal Medicine Physician
CA license A169072 (first issued 2020; current) · MA license L-260076
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 223
- Services billed
- 618
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 164 | 75 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 54 | 21 |
| Established patient office or other outpatient visit, 30-39 minutes | 54 | 41 |
| New patient office or other outpatient visit, 60-74 minutes | 42 | 42 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 40 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 16 |
| Hospital discharge day management, more than 30 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $62.76 in total to this clinician.
| Genentech, Inc. | $48.74 |
|---|---|
| Karyopharm Therapeutics Inc. | $14.02 |
| Food and Beverage | $62.76 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $707,692 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Adc Therapeutics America, Inc. - Ph 1a 1b of aCCR8 in Solid Tumors
Genentech, Inc. - A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Partner Therapeutics, Inc. - Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 (Brigimadlin) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarc…
Boehringer Ingelheim Pharmaceuticals, Inc. - A phase 1B/2 study of TAK-981 plus pembrolizumab to evaluate the safety, tolerability, and antitumor activity of the combination in patients with select advanced or metastatic solid tumors
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.